Transgenic drug gets green light from the united states
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
You have full access to this article via your institution. Download PDF The US Food and Drug Administration (FDA) has issued its first approval of a drug produced by a genetically engineered
animal. The drug, marketed as ATryn, is the human blood protein antithrombin and will be used to treat various blood-clotting disorders. It is produced in the milk of transgenic goats
engineered by GTC Biotherapeutics, a company based in Framingham, Massachusetts. The FDA's decision, released on 6 February, had been delayed while the agency worked out how to regulate
products made from genetically engineered animals. It finally issued industry guidelines on 15 January this year (see _Nature_ 457, 371; 2009), and it was widely expected that approval of
ATryn, which had already been given the green light by a scientific advisory committee, would soon follow. The drug was approved in Europe in June 2006. RIGHTS AND PERMISSIONS Reprints and
permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Transgenic drug gets green light from the United States. _Nature_ 457, 775 (2009). https://doi.org/10.1038/457775e Download citation *
Published: 01 February 2009 * Issue Date: 12 February 2009 * DOI: https://doi.org/10.1038/457775e SHARE THIS ARTICLE Anyone you share the following link with will be able to read this
content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative